118 related articles for article (PubMed ID: 927488)
1. The linear array.
Zubrod CG; Schepartz SA; Carter SK
Natl Cancer Inst Monogr; 1977 Mar; (45):13-4. PubMed ID: 927488
[No Abstract] [Full Text] [Related]
2. Clinical development of anticancer agents--a National Cancer Institute perspective.
Marsoni S; Wittes R
Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
[No Abstract] [Full Text] [Related]
3. The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary.
Venditti JM
Cancer Treat Rep; 1983 Sep; 67(9):767-72. PubMed ID: 6883352
[No Abstract] [Full Text] [Related]
4. Screening at the National Cancer Institute.
Goldin A; Venditti JM; Carter SK
Natl Cancer Inst Monogr; 1977 Mar; (45):37-48. PubMed ID: 337155
[No Abstract] [Full Text] [Related]
5. Historical background of the National Cancer Institute's drug development thrust.
Zubrod CG; Schepartz SA; Carter SK
Natl Cancer Inst Monogr; 1977 Mar; (45):7-11. PubMed ID: 337156
[No Abstract] [Full Text] [Related]
6. Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations.
Natl Cancer Inst Monogr; 1980 Dec; (55):1-179. PubMed ID: 7010179
[No Abstract] [Full Text] [Related]
7. [Past and current problems in tumor research].
von Wasielewski E; Sedlacek HH
Dtsch Med Wochenschr; 1986 Apr; 111(16):630-7. PubMed ID: 3956405
[No Abstract] [Full Text] [Related]
8. [Models and methods used for the selection of antitumor preparations in the USSR and abroad].
Sof'ina ZP
Vopr Onkol; 1976; 22(4):82-96. PubMed ID: 1274284
[No Abstract] [Full Text] [Related]
9. Clinical testing of drugs for cancer in the United States and the Soviet Union.
Holland JF
Natl Cancer Inst Monogr; 1977 Mar; (45):261-2. PubMed ID: 927493
[No Abstract] [Full Text] [Related]
10. [Soviet-American cooperation in experimental and clinical chemotherapy from 1972 to 1979].
Peredovchikova NI; Kiselev AV; Puchkov IuI; Komarova LE; Gorbunova VA
Vopr Onkol; 1980; 26(12):3-6. PubMed ID: 7008350
[No Abstract] [Full Text] [Related]
11. [Introduction of new screening system in National Cancer Institute].
Tsukagoshi S
Gan To Kagaku Ryoho; 1984 May; 11(5):1134-9. PubMed ID: 6539100
[No Abstract] [Full Text] [Related]
12. Modified protocol for the testing of new synthetics in the L1210 lymphoid leukemia murine model in the DR&D program, DCT, NCI.
Geran RI; Greenberg NH; Macdonald MM; Abbott BJ
Natl Cancer Inst Monogr; 1977 Mar; (45):151-3. PubMed ID: 927490
[No Abstract] [Full Text] [Related]
13. Proceedings: Anticancer drug development programs: a comparison of approaches in the United States, the Soviet Union, Japan, and Western Europe.
Carter SK
Natl Cancer Inst Monogr; 1974 Feb; 40():31-45. PubMed ID: 4819407
[No Abstract] [Full Text] [Related]
14. The preclinical new drug research program of the National Cancer Institute.
Driscoll JS
Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
[TBL] [Abstract][Full Text] [Related]
15. The discovery and development of new antileukemic drugs.
Grever M; Malspeis L
Hematol Oncol Clin North Am; 1993 Feb; 7(1):233-54. PubMed ID: 8449860
[TBL] [Abstract][Full Text] [Related]
16. Preclinical toxicology protocols of the Laboratory of Toxicology.
Prieur DJ; Young DM; Davis RD; Cooney DA; Guarino AM
Natl Cancer Inst Monogr; 1977 Mar; (45):159-77. PubMed ID: 412104
[No Abstract] [Full Text] [Related]
17. The NCI Developmental Therapeutics Program.
Collins JM
Clin Adv Hematol Oncol; 2006 Apr; 4(4):271-3. PubMed ID: 16728938
[No Abstract] [Full Text] [Related]
18. Reader comments on complementary and alternative medicine programs.
Lee CO
Clin J Oncol Nurs; 2005 Oct; 9(5):510; author reply 510-1. PubMed ID: 16235577
[No Abstract] [Full Text] [Related]
19. Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson report. June 1966, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Cancer Treat Rep; 1984 Jan; 68(1):343-56. PubMed ID: 6692435
[No Abstract] [Full Text] [Related]
20. Flasks, fibres and flanks--pre-clinical tumour models for predicting clinical antitumour activity.
Newell DR
Br J Cancer; 2001 May; 84(10):1289-90. PubMed ID: 11355935
[No Abstract] [Full Text] [Related]
[Next] [New Search]
